These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3428721)

  • 1. Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.
    Arnout J; van Russelt M; Deckmyn H; Vermylen J
    Haemostasis; 1987; 17(6):344-8. PubMed ID: 3428721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
    De Clerck F; Xhonneux B; Tollenaere JP; Janssen PA
    Thromb Res; 1985 Dec; 40(5):581-96. PubMed ID: 2935970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
    Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
    Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
    Gleerup G; Persson B; Hedner T; Winther K
    Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist.
    De Crée J; Roels V; Verhaegen H
    Drugs; 1988; 36 Suppl 1():87-91. PubMed ID: 3240733
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
    Marasini B; Biondi ML; Mollica R
    Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
    Pietraszek MH; Takada Y; Taminato A; Yoshimi T; Watanabe I; Takada A
    Thromb Res; 1993 Apr; 70(2):131-8. PubMed ID: 8322284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
    Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
    Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
    Meuleman TR; Hill DC; Port JD; Stanley TH; Pace NL; Mohammad SF
    Crit Care Med; 1983 Aug; 11(8):606-11. PubMed ID: 6872549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sodium intake increases platelet aggregation in normal females.
    Gow IF; Padfield PL; Reid M; Stewart SE; Edwards CR; Williams BC
    J Hypertens Suppl; 1987 Dec; 5(5):S243-6. PubMed ID: 3481816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1994 Dec; 43(3-4):225-34. PubMed ID: 7725978
    [No Abstract]   [Full Text] [Related]  

  • 14. Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
    Santini P; Ceccanti M; De Lorenzo A; Pisculli M; Di Giovanni MG; Cavaleri G; Attilia ML; Berbellini A
    Int J Clin Pharmacol Res; 1986; 6(1):73-6. PubMed ID: 2937746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADP plays a key role in thrombogenesis in rats.
    Maffrand JP; Bernat A; Delebassée D; Defreyn G; Cazenave JP; Gordon JL
    Thromb Haemost; 1988 Apr; 59(2):225-30. PubMed ID: 3133809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
    De Clerck F; Xhonneux B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
    Lichtenthal PR; Wade LD; Rossi EC
    Anesth Analg; 1987 Nov; 66(11):1151-4. PubMed ID: 3662060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR
    J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent complexes of albumin with serotonin, ketanserin and lysergic acid antagonize the activity of serotonin in human platelets.
    VandenBerg SR; Gonias SL
    Life Sci; 1989; 44(23):1777-85. PubMed ID: 2733551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.